MIT's dissolving battery powered two swallowed devices in animal tests

The MIT group characterised the degradation curve in a beaker of acid made to resemble stomach fluid: normal operation, a gradual fade in output, then nothing left to recover ^[4]. Until now, every ingestible design had to solve power some other way, by drawing energy from outside the body, harvesting it in the gastrointestinal tract, or carrying a small conventional battery whose contents become a safety question if the protective coating is damaged ^[11].

The therapeutic demonstration used a small slice of the runtime available. Twenty minutes of current against a window of 4,320 minutes is about half a percent of what the cell supported ^[14], and the ghrelin rise was measured at that short dose, in animals ^[6]. Whether the hormone stays elevated under continuous stimulation, and whether appetite or nausea moves with it, are separate questions. According to the Discover account of the work, help for people with nausea or diminished appetite is what might eventually follow ^[7].

The safety argument here is about failure. A cell built from materials the body tolerates in small amounts answers one specific failure case, a capsule that lodges somewhere and breaches its coating ^[3][11]. No regulator or approval pathway is named. Dissolution changes what a retained device can expose someone to. The breakdown schedule comes from simulated gastric fluid ^[4]; the animal experiments demonstrated power delivery to two working devices ^[1].

The team has spent a decade on swallowable electronics, building capsules that track vital signs, administer drugs and identify opioid overdoses ^[10]. SAFARI, the medication-tracking capsule, is the one heading for a clinical trial ^[9].